Literature DB >> 4556544

Clinical screening of epipodophyllotoxin VM26 in malignant lymphomas and solid tumours.

.   

Abstract

Epipodophyllotoxin (VM 26; 4'-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside) has been proved, in clinical screening, to be able to induce apparently complete remissions and pronounced though incomplete regressions in Hodgkin's disease, reticulosarcoma, and bladder cancer, as well as incomplete regressions in lymphosarcoma. Apparently complete regressions of malignant pleural effusions have been obtained after giving this drug systemically. It has a notable toxic action on the bone marrow.

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4556544      PMCID： PMC1788459     

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


  3 in total

1.  Vincristine therapy of lymphomas and chronic lymphocytic leukemia.

Authors:  D V Desal; E Z Ezdinli; L Stutzman
Journal:  Cancer       Date:  1970-08       Impact factor: 6.860

2.  Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids.

Authors:  P P Carbone; C Spurr; M Schneiderman; J Scotto; J F Holland; B Shnider
Journal:  Cancer Res       Date:  1968-05       Impact factor: 12.701

3.  Efficacy of cyclophosphamide in the management of reticulum cell sarcoma.

Authors:  G A Hyman; P A Cassileth
Journal:  Cancer       Date:  1966-10       Impact factor: 6.860
  3 in total
  10 in total

1.  Phase II study of teniposide in advanced breast cancer.

Authors:  J Boas; D Rasmussen; O P Hansen; S A Engelholm; P Dombernowsky
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  New cancer chemotherapy drugs in Europe.

Authors:  G Mathé; L M van Putten
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

Review 3.  [Diagnostic and therapeutic procedures in Hodgkin's disease].

Authors:  D Huhn; C Steidle
Journal:  Blut       Date:  1973-08

Review 4.  New aspects of brain tumor research.

Authors:  K J Zülch; H D Mennel
Journal:  J Neurol       Date:  1977-03-21       Impact factor: 4.849

Review 5.  VM26: phase I and II studies.

Authors:  F R Macbeth
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 6.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

Review 7.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial.

Authors:  E B Cox; C L Vogel; J T Carpenter; M Raney
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850

9.  An operant social self-administration and choice model in rats.

Authors:  Marco Venniro; Yavin Shaham
Journal:  Nat Protoc       Date:  2020-03-20       Impact factor: 13.491

Review 10.  Teniposide: overview of its therapeutic potential in adult cancers.

Authors:  F M Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.